American Association for Cancer Research Annual Meeting, June 2020
American Association for Cancer Research Annual Meeting, June 2020
Publication: The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
Journal for ImmunoTherapy of Cancer, April 2020
Poster: SRF231, a fully human, high affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the FcR, CD32a
Society for Immunotherapy of Cancer Annual Meeting, November 2019
Poster: The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax
American Society of Hematology Annual Meeting, December 2018
Poster: CD47 Monoclonal Antibody SRF231 is a Potent Inducer of Macrophage-Mediated Tumor Cell Phagocytosis and Reduces Tumor Burden in Murine Models of Hematologic Malignancies
American Society of Hematology Annual Meeting, December 2016
Poster: CD47 mAb SRF231 is a Potent Inducer of Macrophage-mediated Tumor Cell Phagocytosis and has Anti-tumor Activity in Preclinical Models
Society for Immunotherapy of Cancer Annual Meeting, November 2016